Minerva Neurosciences, Inc.
NASDAQ:NERVBiotechnology
-$0.30 today
- Market cap
- $108.64M
- Beta
- -0.11
- P/E (TTM)
- -0.2
- EPS (TTM)
- -$8.46
Volume 0.28M
Average 0.21M
NERV EBITDA
Earnings before interest, taxes, depreciation, and amortization; a proxy for operating profit before non-cash and financing charges.
Minerva Neurosciences, Inc.NASDAQ: NERV
EBITDA · Q2 FY2026 · quarter ended Jun 2026
EBITDA turns positive
Q2 FY2026 EBITDA was $17.47M, compared with -$3.26M a year earlier. Trailing-twelve-month EBITDA was -$394.35M.
Context
- EBITDA increased in 2 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly EBITDA holds near $17.47M or moves back toward the trailing-twelve-month quarterly average of -$98.59M.
Sources:Income StatementText generated from reported figures; not investment advice.
EBITDA history
USD · from the income statement
- Latest · FY2025
- (293.42M) USD
- Year-over-year change
- -4971.2%
| Period | Period end | EBITDA | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (293.42M) | -4971.2% |
| FY2024 | 2024-12-31 | 6.02M | +127.8% |
| FY2023 | 2023-12-31 | (21.69M) | +12.2% |
| FY2022 | 2022-12-31 | (24.69M) | +45.5% |
| FY2021 | 2021-12-31 | (45.28M) | — |
EBITDA vs competitors
How NERV compares with its peers on the latest reported figures
- NERV's LTM Jun 2026 EBITDA of -$394.35M is the lowest of the 4 companies compared; the peer median is -$14.32M.
- Its year-over-year change of -3608.6% is the lowest of 4, against a peer median of +12.3%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
NRXSNeurAxis, Inc. | LTM Mar 2026 | -$7.12M | +12.3% | — | 166.2% |
| LTM Dec 2025 | -$14.32M | +2.5% | — | — | |
| LTM Mar 2026 | -$28.06M | +44.2% | — | 3270.4% | |
| LTM Jun 2026 | -$394.35M | -3608.6% | — | — | |
| Peer median (excluding NERV) | -$14.32M | +12.3% | — | 1718.3% | |
Competitors are the stored peer set for NERV. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | 0 | 0 | 0 | 0 | 0 |
| Gross Margin | — | — | — | — | — |
| Research & Development | 32.04M | 14.65M | 12.71M | 11.9M | 5.76M |
| Selling, General & Admin | 13.33M | 10.58M | 10.41M | 9.95M | 9.34M |
| Operating Expenses | 45.37M | 25.23M | 23.12M | 21.85M | 15.1M |
| Depreciation & Amortization | 101.79K | 8.51K | 30.98K | 22.47K | 5.44K |
| EBITDA | (45.28M) | (24.69M) | (21.69M) | 6.02M | (293.42M) |
| EBITDA Margin | — | — | — | — | — |
| Operating Income | (45.37M) | (25.23M) | (23.12M) | (21.85M) | (15.1M) |
| Operating Margin | — | — | — | — | — |
| Interest Income | 16.52K | 556.95K | 1.44M | 1.27M | 948.12K |
| Interest Expense | 6.33M | 7.41M | 8.28M | 4.56M | 0 |
| Other Income / Expenses | (6.34M) | (6.88M) | (6.89M) | 23.29M | (278.32M) |
| Income Before Tax | (51.71M) | (32.11M) | (30.01M) | 1.44M | (293.42M) |
| Pre-Tax Margin | — | — | — | — | — |
| Income Tax Expense | (1.8M) | 0 | 0 | 0 | 0 |
| Net Income | (49.91M) | (32.11M) | (30.01M) | 1.44M | (293.42M) |
| Net Margin | — | — | — | — | — |
| EPS (Basic) | (9.35) | (6.01) | (4.61) | 0.19 | (34.67) |
| EPS (Diluted) | (9.35) | (6.01) | (4.61) | 0.19 | (34.67) |
| Weighted Avg Shares | 5.34M | 5.34M | 6.51M | 7.57M | 8.46M |
| Weighted Avg Shares (Diluted) | 5.34M | 5.34M | 6.51M | 7.57M | 8.46M |
Minerva Neurosciences, Inc.
NASDAQ:NERV
Intrinsic Alpha fair value
Locked
Current Price
$2.18
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.